MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data

ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data

By

ACC '18Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure.

Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session.

More than 1,000 patients participated in the study. Researchers assessed the trial’s participants for a short-term endpoint of six months and long-term endpoint of two years.

The two-year cohort met its primary endpoint, achieving 77.9% event-free survival – topping the 56.4% rate seen in patients treated with the HeartMate II LVAD.

Patients treated with the HeartMate 3 device had a survival rate of 82.8% after two years, compared to 76.2% for the HeartMate II group. Abbott also reported that low pump thrombosis rates remained low at 1.2% for the HeartMate 3 group, with no reoperations or pump replacements needed at two years.

Finally, the stroke rate in the HeartMate 2 group was 19% compared to just 10% for the patients treated with HeartMate 3.

“The long-term data for the pivotal Momentum 3 trial demonstrate overall survival of 83% at 2-years and marked improvement in clinical outcomes for our patients suffering with advanced heart failure,” Dr. Mandeep Mehra, medical director of Brigham and Women’s Hospital Heart and Vascular Center, said in prepared remarks. “We have seen greater pump durability—mostly driven by an absence of confirmed pump thrombosis—as well as a significantly lowered stroke rate without an increase in other adverse events.”

“As the leader in LVAD therapy, our goal is to provide patients with life-changing health technology that minimizes risk and offers them an enhanced quality of life. Data from the Momentum 3 study show Abbott’s significant progress in LVAD innovation and how it’s improving patient health outcomes,” Dr. John O’Connell, medical director for Abbott’s mechanical circulatory support business, added.

Abbott’s HeartMate 3 LVAD has CE Mark clearance in the E.U. and is approved by the FDA in the U.S. for short-term use. The company plans to use data from its Momentum 3 trial to support an regulatory bid for a long-term indication for HeartMate 3 in the U.S.

NEXT: Philips touts NEJM study on iFR v. FFR

In case you missed it

RSS From Medical Design & Outsourcing

  • Wytech Industries names new president
    Specialty and precision wire manufacturer Wytech Industries (Rahway, N.J.) today announced it has named David Ohmann as president. Ohmann has nearly 25 years of experience in international, orthopedic and advanced surgical medical device segments. Prior to joining Wytech, Ohmann held sales and marketing leadership positions at Heraeus and MicroGroup (a TE Connectivity company). Ohmann has a… […]
  • Spectrum Plastics acquires Laser Light Technologies
    Spectrum Plastics Group has announced the acquisition of substantially all assets of Laser Light Technologies. An ISO 9001- and ISO 13485-certified organization based in Hermann, Mo., Laser Light Technologies provides custom laser processing systems and services using excimer, femtosecond, picosecond and YAG laser technologies. “The addition of the talented team at Laser Light Technologies brings… […]
  • Dymax announces deal with coatings company
    Dymax and nanocoatings manufacturer HZO today announced a strategic partnership. The deal will add 3,000 coatings formulations to HZO’s portfolio, facilitate joint product development, and use Dymax’s global sales channel to extend market reach. Dymax (Torrington, Conn.) manufactures rapid light-cure adhesives, conformal coatings, potting compounds and complementary dispensing and curing equipment used in medtech and… […]
  • Qosina releases 2022 catalog
    Qosina said today it has released the latest edition of its product catalog in both print and digital formats. The 2022 product catalog includes thousands of single-use medical and pharma components depicted in full-scale photos on a one-centimeter grid to help design engineers visualize their next-generation medical device, according to the Ronkonkoma, N,.Y.-based company. Qosina… […]
  • Medline completes $1.5B spending plan
    Medline Industries announced this week that it has completed a three-year, $1.5 billion capital spending campaign. The Northfield, Ill.-based company, which is reportedly up for sale, said it invested the money in new distribution centers, manufacturing capabilities and IT upgrades to improve customers’ e-commerce experience. All told, the initiative added approximately 8,500 new jobs, eight… […]
  • Clippard touts flow controller with high resolution and repeatability in a closed-loop system
    Clippard recently announced the release of its Cordis flow controller, which uses a MEMS technology sensor upstream from a proportional valve. There’s also an option for a DR-2 regulator to provide accurate and precise pressure control in a small package. Said Clippard: “Unlike other mass flow controllers that require a 30-minute warm-up time, large differential… […]
  • FDA clears DBS targeting software
    Surgical Information Sciences (SIS) recently won FDA clearance for software designed to guide deep-brain stimulation (DBS) procedures. The Plymouth, Minn.-based company’s software uses deep learning models to identify brain structures such as the subthalamic nuclei (STN) and globus pallidus internus/externus (GPi/GPe) commonly targeted for DBS procedures. The SIS system provides visualization of these structures for… […]
  • Cerapedics’ bone graft gains FDA breakthrough nod
    Ortho-biologics company Cerapedics announced that it has won FDA breakthrough device designation for its investigational P-15L bone graft to treat degenerative disc disease (DDD). The company plans to enroll at least 270 DDD patients in the Aspire study, a prospective, single-blinded, multi-center, randomized, non-inferiority pivotal IDE study to evaluate the safety and efficacy of P-15L… […]
  • FDA revokes Battelle mask decontamination EUA
    The FDA has revoked its authorization for Battelle Memorial Institute to decontaminate used N95 respirators for healthcare workers. In a letter dated April 30, 2021, the agency said it revoked the EUA at Battelle’s request. The Columbus, Ohio-based research organization asked to withdraw the EUA for its Critical Care Decontamination System (CCDS) in an April… […]
  • The importance of a valve’s soft start for critical applications requiring high precision
    When a valve is cycled, one can observe the quality of control by measuring and graphing the flow leaving the valve and the input operating the valve, such as electrical current (for coil controlled valves) or steps (for stepper motor controlled valves). This paper will discuss the characteristics of a valve’s performance curve—specifically, where flow… […]
  • 5 IP tips for medical device entrepreneurs
    Taking certain steps — including some that are easily overlooked — can better protect your intellectual property. Thinking of designing your own medical device or launching a company? In recent DeviceTalks Weekly podcasts, two partners from the intellectual property law firm Finnegan, Henderson, Farabow, Garrett & Dunner, LLP shared several tips medical device company executives… […]